Durham biotech triples workforce as FDA decision looms

The FDA is expected to make its decision on Priovant's application for brepocitinib in the third quarter. The health care ...

Durham biotech surges workforce as FDA decision looms

The FDA is expected to make its decision on Priovant's application for brepocitinib in the third quarter.

An adviser’s fund pairing needs a closer look

First, it’s important to know that these are two different creatures and shouldn’t be lumped together under the term exchange ...